ARCHIVES

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 10 | October 26, 2001

Download PDF Visit The Full Archive

Related Articles

Government Offers Two Approval Standards For Assays: CLIA, FDA

January 30, 2009

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

December 5, 2014

NCI CTEP Approved Trials For the Month of February

February 22, 2013

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

January 25, 2013

NCAB Approves Grants For Action Plan On Breast Cancer

September 22, 1995

ECOG, ACRIN Form Single Cooperative Group

May 18, 2012